Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Jul 12. pii: 10.1212/WNL.0000000000007938. doi: 10.1212/WNL.0000000000007938. [Epub ahead of print]

PMID:
31300547
2.

Joint assessment of brain and spinal cord motor tract damage in patients with early RRMS: predominant impact of spinal cord lesions on motor function.

Chouteau R, Combès B, Bannier E, Snoussi H, Ferré JC, Barillot C, Edan G, Sauleau P, Kerbrat A.

J Neurol. 2019 Jun 7. doi: 10.1007/s00415-019-09419-5. [Epub ahead of print]

PMID:
31175433
3.

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.

Ahrweiller K, Rousseau C, Le Page E, Bajeux E, Leray E, Michel L, Edan G, Kerbrat A.

Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090. [Epub ahead of print]

PMID:
31094285
4.

Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.

Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleur NM, Carra-Dalliere C, Charif M, Collongues N, de Seze J, Hebbadj S, Ahle G, Oesterlé H, Cotton F, Durand-Dubief F, Marignier R, Vukusic S, Taithe F, Cohen M, Guennoc AM, Kerbrat A, Edan G, Carsin-Nicol B, Allou T, Sablot D, Thouvenot E, Ruet A, Magy L, Boncoeur-Martel MP, Labauge P, Kremer S.

J Neurol. 2019 Jul;266(7):1743-1755. doi: 10.1007/s00415-019-09328-7. Epub 2019 Apr 23.

PMID:
31016376
5.

Multiple sclerosis: effect of beta interferon treatment on survival.

Kingwell E, Leray E, Zhu F, Petkau J, Edan G, Oger J, Tremlett H.

Brain. 2019 May 1;142(5):1324-1333. doi: 10.1093/brain/awz055.

PMID:
30883636
6.

Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.

Eden D, Gros C, Badji A, Dupont SM, De Leener B, Maranzano J, Zhuoquiong R, Liu Y, Granberg T, Ouellette R, Stawiarz L, Hillert J, Talbott J, Bannier E, Kerbrat A, Edan G, Labauge P, Callot V, Pelletier J, Audoin B, Rasoanandrianina H, Brisset JC, Valsasina P, Rocca MA, Filippi M, Bakshi R, Tauhid S, Prados F, Yiannakas M, Kearney H, Ciccarelli O, Smith SA, Andrada Treaba C, Mainero C, Lefeuvre J, Reich DS, Nair G, Shepherd TM, Charlson E, Tachibana Y, Hori M, Kamiya K, Chougar L, Narayanan S, Cohen-Adad J.

Brain. 2019 Mar 1;142(3):633-646. doi: 10.1093/brain/awy352.

PMID:
30715195
7.

First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre study.

Lavandier N, Bonnan M, Carra-Dallière C, Charif M, Labauge P, Camdessanche JP, Edan G, Naudin A, Brassat D, Ciron J, Clavelou P, Dulau C, Moroso A, Brochet B, Ouallet JC; on behalf Société Francophone de la Sclérose en Plaques (SFSEP).

Mult Scler Relat Disord. 2019 Feb;28:309-312. doi: 10.1016/j.msard.2018.12.016. Epub 2018 Dec 14.

PMID:
30665072
8.

Measurement of magnetization transfer ratio (MTR) from cervical spinal cord: Multicenter reproducibility and variability.

Combès B, Monteau L, Bannier E, Callot V, Labauge P, Ayrignac X, Carra Dallière C, Pelletier J, Maarouf A, de Seze J, Collongues N, Barillot C, Edan G, Ferré JC, Kerbrat A; EMISEP study group.

J Magn Reson Imaging. 2019 Jun;49(6):1777-1785. doi: 10.1002/jmri.26537. Epub 2018 Oct 22.

PMID:
30350328
9.

Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks.

Gros C, De Leener B, Badji A, Maranzano J, Eden D, Dupont SM, Talbott J, Zhuoquiong R, Liu Y, Granberg T, Ouellette R, Tachibana Y, Hori M, Kamiya K, Chougar L, Stawiarz L, Hillert J, Bannier E, Kerbrat A, Edan G, Labauge P, Callot V, Pelletier J, Audoin B, Rasoanandrianina H, Brisset JC, Valsasina P, Rocca MA, Filippi M, Bakshi R, Tauhid S, Prados F, Yiannakas M, Kearney H, Ciccarelli O, Smith S, Treaba CA, Mainero C, Lefeuvre J, Reich DS, Nair G, Auclair V, McLaren DG, Martin AR, Fehlings MG, Vahdat S, Khatibi A, Doyon J, Shepherd T, Charlson E, Narayanan S, Cohen-Adad J.

Neuroimage. 2019 Jan 1;184:901-915. doi: 10.1016/j.neuroimage.2018.09.081. Epub 2018 Oct 6.

PMID:
30300751
10.

Where there is inflammation, treatment may reduce disability progression - No.

Edan G, Vukusic S.

Mult Scler. 2018 Oct 8:1352458518795417. doi: 10.1177/1352458518795417. [Epub ahead of print] No abstract available.

PMID:
30295565
11.

Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure.

Commowick O, Istace A, Kain M, Laurent B, Leray F, Simon M, Pop SC, Girard P, Améli R, Ferré JC, Kerbrat A, Tourdias T, Cervenansky F, Glatard T, Beaumont J, Doyle S, Forbes F, Knight J, Khademi A, Mahbod A, Wang C, McKinley R, Wagner F, Muschelli J, Sweeney E, Roura E, Lladó X, Santos MM, Santos WP, Silva-Filho AG, Tomas-Fernandez X, Urien H, Bloch I, Valverde S, Cabezas M, Vera-Olmos FJ, Malpica N, Guttmann C, Vukusic S, Edan G, Dojat M, Styner M, Warfield SK, Cotton F, Barillot C.

Sci Rep. 2018 Sep 12;8(1):13650. doi: 10.1038/s41598-018-31911-7.

12.

Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?

Guennoc AM, Pallix-Guyot M, Le Page E, Le Port D, Daryabin M, Hergesheimer R, Beltran S, Tourbah A, Edan G, Corcia P.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):500-505. doi: 10.1080/21678421.2018.1476547. Epub 2018 Sep 3.

PMID:
30175630
13.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9942-9. [Epub ahead of print]

PMID:
30155789
14.

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S; Société Francophone de la Sclérose en Plaques.

J Neurol. 2018 Oct;265(10):2251-2259. doi: 10.1007/s00415-018-8984-7. Epub 2018 Jul 27.

PMID:
30054790
15.

Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.

Combès B, Kerbrat A, Ferré JC, Callot V, Maranzano J, Badji A, Le Page E, Labauge P, Ayrignac X, Carra Dallière C, de Champfleur NM, Pelletier J, Maarouf A, de Seze J, Collongues N, Brassat D, Durand-Dubief F, Barillot C, Bannier E, Edan G.

Mult Scler. 2019 Jul;25(8):1113-1123. doi: 10.1177/1352458518781999. Epub 2018 Jun 18.

PMID:
29909771
16.

Multiple Sclerosis over the last 25 years: an introduction.

Edan G.

Rev Neurol (Paris). 2018 Jun;174(6):353-354. doi: 10.1016/j.neurol.2018.04.008. No abstract available.

PMID:
29903397
17.

Induction or escalation therapy for patients with multiple sclerosis?

Le Page E, Edan G.

Rev Neurol (Paris). 2018 Jun;174(6):449-457. doi: 10.1016/j.neurol.2018.04.004. Epub 2018 May 22. Review.

18.

Natalizumab in secondary progressive multiple sclerosis.

Edan G.

Lancet Neurol. 2018 May;17(5):384-385. doi: 10.1016/S1474-4422(18)30108-X. Epub 2018 Mar 12. No abstract available.

19.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2019 Apr;25(4):565-573. doi: 10.1177/1352458518763089. Epub 2018 Mar 9.

PMID:
29521573
20.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
21.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
22.

Foreword.

Timsit S, Edan G.

Rev Neurol (Paris). 2017 Nov;173(9):552-553. doi: 10.1016/j.neurol.2017.10.014. No abstract available.

PMID:
29101927
23.

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up.

Kerbrat A, Combès B, Commowick O, Maarouf A, Bannier E, Ferré JC, Tourbah A, Ranjeva JP, Barillot C, Edan G.

Mult Scler. 2017 Oct 1:1352458517736148. doi: 10.1177/1352458517736148. [Epub ahead of print]

PMID:
29064775
24.

Small-area distribution of multiple sclerosis incidence in western France: in search of environmental triggers.

Hammas K, Yaouanq J, Lannes M, Edan G, Viel JF.

Int J Health Geogr. 2017 Sep 21;16(1):35. doi: 10.1186/s12942-017-0108-6.

25.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

26.

Oral rather than intravenous corticosteroids should be used to treat MS relapses - Yes.

Le Page E, Edan G.

Mult Scler. 2017 Jul;23(8):1056-1058. doi: 10.1177/1352458517695893. Epub 2017 Feb 1. No abstract available.

PMID:
28326884
27.

An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.

Kalson-Ray S, Edan G, Leray E; SURVIMUS Study Group.

Mult Scler. 2017 May;23(6):864-871. doi: 10.1177/1352458517699873. Epub 2017 Mar 16.

PMID:
28299961
28.

Adress from the President, January 2017.

Edan G.

Rev Neurol (Paris). 2017 Jan - Feb;173(1-2):4-5. doi: 10.1016/j.neurol.2017.01.398. French. No abstract available.

PMID:
28212830
29.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
30.

Inhibitor of Fatty Acid Amide Hydrolase - Learning from Tragic Failures.

Edan G, Kerbrat A.

N Engl J Med. 2017 Jan 26;376(4):393-4. doi: 10.1056/NEJMc1615417. No abstract available.

PMID:
28121500
31.

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F.

PLoS One. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556. eCollection 2016.

32.

Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.

Kerbrat A, Ferré JC, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, Lavoué S, Vérin M, Gauvrit JY, Le Tulzo Y, Edan G.

N Engl J Med. 2016 Nov 3;375(18):1717-1725.

33.

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

Bonenfant J, Bajeux E, Deburghgraeve V, Le Page E, Edan G, Kerbrat A.

Eur J Neurol. 2017 Feb;24(2):237-244. doi: 10.1111/ene.13181. Epub 2016 Oct 18.

PMID:
27753181
34.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

35.

[Rapid improvement in visual function after high-dose oral corticosteroids in patients with inflammatory optic neuropathy].

Poujade A, Le Page E, Baudet D, Edan G, Mortemousque B, Mouriaux F.

J Fr Ophtalmol. 2016 Oct;39(8):691-699. doi: 10.1016/j.jfo.2016.03.008. Epub 2016 Aug 24. French.

36.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

37.

Progressive multifocal leukoencephalopathy in a patient with silicosis.

Bonnet A, Kerbrat A, Tattevin P, Salmon A, Jouneau S, Edan G, Gasnault J.

J Neurol. 2016 Sep;263(9):1866-8. doi: 10.1007/s00415-016-8216-y. Epub 2016 Jul 14. No abstract available.

PMID:
27416854
38.

Imaging biomarkers in multiple Sclerosis: From image analysis to population imaging.

Barillot C, Edan G, Commowick O.

Med Image Anal. 2016 Oct;33:134-139. doi: 10.1016/j.media.2016.06.017. Epub 2016 Jun 15.

PMID:
27374128
39.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

40.

Epidemiology of multiple sclerosis.

Leray E, Moreau T, Fromont A, Edan G.

Rev Neurol (Paris). 2016 Jan;172(1):3-13. doi: 10.1016/j.neurol.2015.10.006. Epub 2015 Dec 21.

PMID:
26718593
41.

Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome.

Maarouf A, Ferré JC, Zaaraoui W, Le Troter A, Bannier E, Berry I, Guye M, Pierot L, Barillot C, Pelletier J, Tourbah A, Edan G, Audoin B, Ranjeva JP.

Mult Scler. 2016 Jul;22(8):1032-9. doi: 10.1177/1352458515607649. Epub 2015 Oct 9.

42.

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.

Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A.

Neurology. 2015 Nov 10;85(19):1694-701. doi: 10.1212/WNL.0000000000002099. Epub 2015 Oct 9.

43.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
44.

Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.

Gonsette R, Debouverie M, Sindic C, Ferré JC, Edan G.

Mult Scler. 2016 May;22(6):817-21. doi: 10.1177/1352458515601902. Epub 2015 Aug 18.

PMID:
26286699
45.

Spinal cord hemorrhage in a patient with neurosarcoidosis on long-term corticosteroid therapy: case report.

Pegat B, Drapier S, Morandi X, Edan G.

BMC Neurol. 2015 Jul 30;15:123. doi: 10.1186/s12883-015-0373-6.

46.

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.

PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015.

47.

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G; COPOUSEP investigators; West Network for Excellence in Neuroscience.

Lancet. 2015 Sep 5;386(9997):974-81. doi: 10.1016/S0140-6736(15)61137-0. Epub 2015 Jun 28. Erratum in: Lancet. 2016 Jan 23;387(10016):340.

48.

A retrospective study on the efficacy and safety of intraveinous immunoglobulin (Tegeline®) in patients with chronic inflammatory demyelinating polyneuropathy.

Robert F, Edan G, Nicolas G, Pouget J, Vial C, Antoine JC, Puget S.

Presse Med. 2015 Jul-Aug;44(7-8):e291-300. doi: 10.1016/j.lpm.2014.10.021. Epub 2015 Jun 9.

PMID:
26071027
49.

Diffusion MRI abnormalities detection with orientation distribution functions: a multiple sclerosis longitudinal study.

Commowick O, Maarouf A, Ferré JC, Ranjeva JP, Edan G, Barillot C.

Med Image Anal. 2015 May;22(1):114-23. doi: 10.1016/j.media.2015.02.005. Epub 2015 Mar 20.

50.

Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.

Le Page E, Deburghgraeve V, Lester MA, Cardiet I, Leray E, Edan G.

J Neurol. 2015;262(4):1024-34. doi: 10.1007/s00415-015-7653-3. Epub 2015 Feb 21.

PMID:
25701008

Supplemental Content

Support Center